Market News

Lyra Therapeutics Exceeds EPS Expectations but Falls Short on Revenue in Q4 2023

by Ron Finklestien

Published On: March 21, 2024 11:50 pm

LYRA stock - LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023

Source: iQoncept / Shutterstock

Lyra Therapeutics (NASDAQ:LYRA) has recently revealed its performance figures for the fourth quarter of 2023.

Lyra Therapeutics posted earnings per share of -22 cents, surpassing the projected EPS of -31 cents by analysts.
The company’s revenue totaled $146,000, falling significantly short by 62.56% compared to the anticipated revenue of $390,000.

InvestorPlace Earnings initiative, powered by data from TradeSmith, serves to automatically cover quarterly earnings reports. This project distills crucial highlights like earnings per share, revenue, and the company’s alignment with analyst forecasts. The articles are disseminated without direct human input, ensuring expeditious delivery of the latest financial metrics to our readers. Should you encounter any concerns or discrepancies, please reach out to us at [email protected].

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/lyra-stock-earnings-lyra-therapeutics-for-q4-of-2023/.

Lyra Therapeutics Exceeds EPS Expectations but Falls Short on Revenue in Q4 2023

The free Daily Market Overview 250k traders and investors are reading

Latest Stories

Latest

Brazil’s Coffee Harvest Challenges Impact Market Prices

Soybean Prices Surge Midweek Driven by Strong Product Demand

Wheat Recovery After Initial Decline

Corn Demonstrates Strong Midday Performance

Hogs Rallying on Wednesday

Wheat Prices Surge at Market Close

Categories

Links

Follow Us On